RxDoctor Payments Data

Tad Seifert, MD

Neurology · Louisville, KYNPI 1932285012

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $75,355 of the $98,594 with a category attached, or 76.4%. 10 manufacturers reported payments, led by AbbVie at 44.9% of the total. Reporting peaked in 2020 at $45,954 and has fallen 99.7% since, to $144 in 2025. Among neurology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$98,594in general payments, 2019–2025

Across 316 payments — averaging $312.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$44K
  • Amgen$22K
  • Lilly USA, LLC$17K
  • Lundbeck LLC$6K
  • Supernus Pharmaceuticals, Inc.$6K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $399 from 4 others

What the payments were for

  • Consulting fees$14,92015%
  • Speaking & faculty fees$75,35576%
  • Travel & lodging$4,0334%
  • Food & beverage$4,2784%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,594 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$21,337
Medicare patients
66
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe78$75,731
Nurtec OdtRimegepant Sulfate51$72,801
UbrelvyUbrogepant51$52,099
QuliptaAtogepant24$27,762
Emgality PenGalcanezumab-Gnlm29$23,899
Sumatriptan Succinate17$1,208
Topiramate96$919
Naratriptan Hcl20$861
Memantine Hcl22$778
Gabapentin55$565
Eletriptan HbrEletriptan Hydrobromide27$551
Amitriptyline Hcl30$419
RizatriptanRizatriptan Benzoate13$414
Promethazine Hcl33$334
Levetiracetam16$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$44,294$79,86175 claims
PfizerNurtec Odt$215$72,80151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →